Primary resistance to highly selective RET inhibitors is rare, occurring in around 2% of MTC patients on selpercatinib in clinical trials (Wirth et al. 2020, Hadoux et al. 2023a,b). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.